# Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

> **NCT00040144** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 85 (—)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ACH126, 433

## Key facts

- **NCT ID:** NCT00040144
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 85 (—)
- **Why stopped:** Safety concerns
- **Last updated:** 2021-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040144, "Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00040144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*